Clearance Summary
NHancer Rx received FDA 510(k) clearance under submission number K200324, sponsored by Imds Operations B.V.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Cardiovascular review panel. The statutory decision date of record is 2020-08-06.
- Submission: K200324
- Applicant / Sponsor: Imds Operations B.V.
- Clearance pathway: Traditional
- Review panel: Cardiovascular
- Device class: Class II
- Regulation citation: 21 CFR 870.1250
- Decision date: 2020-08-06
Classification & Regulation
This clearance is catalogued under FDA product code DQY and 21 CFR 870.1250, within the Cardiovascular review panel as a Class II device.